PR Newswire PharmaOriginal article
New Johnson & Johnson ICOTYDE® (icotrokinra) long-term data demonstrate robust 2-year results in the treatment of adults and adolescents with plaque psoriasis
Data ReadoutpositiveICOTYDE®Positive
AI Analysis
Summary
Johnson & Johnson presented Phase 3 2-year data for ICOTYDE® (icotrokinra) in plaque psoriasis, demonstrating high sustained response rates with nearly 75% of patients achieving clear or almost clear skin and a favorable safety profile.
Clinical Trial Data
Phase
Phase 3
Primary Endpoint
Met
Outcome Details
Phase 3 long-term 2-year data showed high sustained response rates with nearly three-quarters of adults and adolescents achieving clear or almost clear skin, with continued favorable safety profile
Importance:7/10
Sentiment:
0.80
dermatologypsoriasislong-term dataPhase 3positive results
Related Companies
Read the original article
Published by PR Newswire Pharma on October 9, 2026 11:00 AM